A leveraged dental-tech titan at multi-year lows: XRAY is a “show-me” turnaround where cost cuts and cloud hopes must outrun Byte damage, U.S. collapse, and balance-sheet pressure.
Overview
Dentsply Sirona (XRAY), the largest global manufacturer of professional dental products, enters 2026 in a distressed turnaround after a decade of underperformance following the 2016 DENTSPLY/Sirona merger. The original “end-to-end” vision—integrating consumables with premium digital equipment—has been undermined by integration friction, strategic missteps, and capital misallocation. The crisis peaked in 2024–2025 with the implosion of the Byte direct-to-consumer aligner strategy, triggering major impairments ($495M in Q3’24; $263M in Q3’25) and accelerating revenue deterioration. In Q3’25, net sales were $904M (-5% reported; -8% constant currency), highlighted by a severe U.S. decline (-22.2%), suggesting structural problems rather than simple cyclicality. While Wellspect Healthcare delivered resilient growth (+9.3% constant currency), core dental segments remain pressured: CTS faces a capex freeze and hardware saturation amplified by high rates, and OIS/implants are losing share to both premium and value competitors. Leadership reset is underway with CEO Daniel Scavilla (appointed Aug-2025), but execution risk is elevated given governance disruption and the abrupt CFO departure (Nov-2025). The investment debate centers on whether the “Return to Growth” restructuring can generate sufficient cost savings and accelerate the cloud transition (DS Core, Primescan 2) fast enough to stabilize revenue before leverage and covenants force a dividend cut or asset sales. With the stock near multi-year lows, the market is discounting a high probability of a value-trap outcome where the low multiple masks a shrinking earnings base and balance-sheet fragility.